Last update April 15, 2024
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Бозентан is Bosentan in Cyrillic.
Is written in other languages:Бозентан belongs to this group or family:
Main tradenames from several countries containing Бозентан in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 50 | % |
Molecular weight | 552 | daltons |
Protein Binding | 98 | % |
VD | 0.26 | l/Kg |
Tmax | 3 - 5 | hours |
T½ | 5 | hours |
Theoretical Dose | 0.0003 - 0.0006 | mg/Kg/d |
Relative Dose | 0.24 | % |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is an endothelin receptor antagonist. Indicated in the treatment of idiopathic pulmonary arterial hypertension or hypertension associated with connective tissue disease or heart disease. Oral administration twice daily.
Its pharmacokinetic data (moderately high molecular weight, high percentage of protein binding, high volume of distribution and acidic pKa) explain the very low passage into breast milk observed. (Nauwelaerts 2022)
Its low oral bioavailability makes it difficult to pass into infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period, where there may be greater intestinal permeability.
A 30-week preterm infant who was breastfed for 2.5 months on Bosentan and Sildenafil did not have any problems (Molelekwa 2005). An infant breastfed for more than 21 months, with the mother taking Bosentan and Sildenafil from 6 months after birth, had no clinical problems with partial breastfeeding. (Nauwelaerts 2022)
It is used in Pediatrics from 1 year of age or 10 kg of weight and there are publications with neonatal use and in premature infants with very good tolerance. (Fatima 2018, Pediamecum 2014, Nakwan 2009, Maingourd 2008, Maiya 2006, Rosenzweig 2005, Molelekwa 2005, Barst 2003)